Pacific 8 Ventures
VC Fund
Taipei, Taiwan
Pacific 8 Ventures is a venture capital firm focusing on transformative technologies changing healthcare
- Total investments:
- 19
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries Pacific 8 Ventures invests in
Stages Pacific 8 Ventures invests in
Countries Pacific 8 Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.1M–$9M
- Series A
- $3.4M–$59M
Investment Focus
Industry
- Health Care 7 (37%)
- Biotechnology 5 (26%)
- Information Technology 5 (26%)
- Medical 4 (21%)
- Genetics 3 (16%)
Stage
- Seed 8 (42%)
- Series A 6 (32%)
- Pre-Seed 1 (5%)
- Series B 1 (5%)
- Series C 1 (5%)
Country
- United States 12 (63%)
- Austria 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Chris Shu
Founding Managing Partner
|
Founding Managing Partner | Total investments: 3 | Find email | |
Jack Liang
Founding Partner
|
Founding Partner | Total investments: 0 | Find email | |
Ser-Chen Fu
Partner
|
Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Certainly Health
|
Certainly Health is a healthcare marketplace for insured patients to compare guaranteed out-of-pocket costs across doctors. | $2.3M / Seed / Dec 13, 2023 | |
BillionToOne
|
BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to makepre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries.BillionToOne was founded in 2016 and is headquartered in Menlo Park, California. | $125M / Series C / Mar 30, 2022 | |
Fauna Bio
|
Fauna Bio is developing new ways to treat human diseases, such as heart disease and neurodegenerative disease, by adopting mechanisms animals have developed for traits such as hibernation and deep-diving. Founded by three scientists who have intimate knowledge of the best science and resources from the field of non-model organisms, Fauna Bioleverages data from hundreds of species in order to help develop pre-clinical and early clinical testing for new therapeutics targeting human diseases. | $9M / Seed / Sep 21, 2021 | |
Bunkerhill Health
|
AI agents for modern health systems | Seed / Dec 01, 2020 | |
|
Bunkerhill Health
|
AI agents for modern health systems | Pre-Seed / Dec 01, 2020 | |
|
BillionToOne
|
BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to makepre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries.BillionToOne was founded in 2016 and is headquartered in Menlo Park, California. | $15M / Series A / Mar 10, 2020 | |
hi.health
|
We are reinventing the claims process in private health insurance (PHI). Existing claims processes suffer from significant friction in the user journey and a lack of cost control for insurers. We eliminate the friction in this process while putting effective cost controls in place. Our solution is to provide insurers with co-branded debit cardsdistributed to their members. Each member can use their card at any health-related facility in the world - eliminating out-of-pocket expenses entirely. Think of corporate spend management providers like Payhawk, only for international and domestic private health insurers. So, the advantages are obvious: we help insurers to provide a 10x better user experience and to achieve substantial cost savings by providing structured data, offering real-time visibility on claims costs, minimizing fraudulent claims, and implementing a reward/cashback program to steer user behavior. | $3.3M / Seed / Feb 04, 2020 | |
Mammoth Biosciences
|
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth Biosciences aims to democratize disease detection with an easy and affordablepoint-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, and Cas14, Mammoth Biosciences can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in South San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng Capital and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.Mammoth has also been working on developing a rapid COVID-19 test. | $45M / Series B / Jan 30, 2020 | |
|
Fauna Bio
|
Fauna Bio is developing new ways to treat human diseases, such as heart disease and neurodegenerative disease, by adopting mechanisms animals have developed for traits such as hibernation and deep-diving. Founded by three scientists who have intimate knowledge of the best science and resources from the field of non-model organisms, Fauna Bioleverages data from hundreds of species in order to help develop pre-clinical and early clinical testing for new therapeutics targeting human diseases. | $4.1M / Seed / Apr 11, 2019 | |
Hint Health
|
Hint Health powers tomorrow's healthcare providers by giving them the tools they need to operate and administer their own plans, and by doing so compete directly with insurance-based models. Based in San Francisco and backed by top investors, Hint’s mission is to fix the broken healthcare system by fundamentally restructuring the way that careis delivered. Hint was co-founded in late 2013 by Stanford GSB alum Zak Holdsworth and CTO Graham Melcher.Their annual conference Hint Summit (summit.hint.com) brings together pioneering physicians, industry leaders, technology experts, and policy advocates who are at the forefront of healthcare reform in the US, to accelerate direct care and make it the new standard. | $10M / Series A / May 08, 2018 | |
| See all 19 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Pacific 8 Ventures invest in?
Pacific 8 Ventures invests primarily in Health Care, Biotechnology and Information Technology startups, most often at Seed and Series A stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Pacific 8 Ventures's check size?
Pacific 8 Ventures typically joins rounds of $1.1M–$9M at Seed and $3.4M–$59M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Pacific 8 Ventures participates in.
How do I contact Pacific 8 Ventures?
Public channels for Pacific 8 Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Pacific 8 Ventures?
The team at Pacific 8 Ventures includes Chris Shu (Founding Managing Partner), Jack Liang (Founding Partner) and Ser-Chen Fu (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
